Pasar al contenido principal

ACTIVACION INAPROPIADA DEL RECEPTOR DE MINERALOCORTICOIDES: FISIOPATOLOGIA Y MECANISMOS

BFU2016-78374-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE LA LAGUNA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phenotypic modulation of cultured primary human aortic vascular smooth muscle cells by uremic serum

  • Cazaña-Pérez, Violeta
  • Cidad, Pilar
  • Donate-Correa, Javier
  • Martín-Núñez, Ernesto
  • López-López, José R.
  • Pérez-García, M. Teresa
  • Giraldez, Teresa
  • Navarro-González, Juan F.
  • Alvarez de la Rosa, Diego
Patients with chronic kidney disease (CKD) have a markedly increased incidence of cardiovascular disease (CVD). The high concentration of circulating uremic toxins and alterations in mineral metabolism and hormone levels produce vascular wall remodeling and significant vascular damage. Medial calcification is an early vascular event in CKD patients and is associated to apoptosis or necrosis and trans-differentiation of vascular smooth muscle cells (VSMC) to an osteogenic phenotype. VSMC obtained from bovine or rat aorta and cultured in the presence of increased inorganic phosphate (Pi) have been extensively used to study these processes. In this study we used human aortic VSMC primary cultures to compare the effects of increased Pi to treatment with serum obtained from uremic patients. Uremic serum induced calcification, trans-differentiation and phenotypic remodeling even with normal Pi levels. In spite of similar calcification kinetics, there were fundamental differences in osteochondrogenic marker expression and alkaline phosphatase induction between Pi and uremic serum-treated cells. Moreover, high Pi induced a dramatic decrease in cell viability, while uremic serum preserved it. In summary, our data suggests that primary cultures of human VSMC treated with serum from uremic patients provides a more informative model for the study of vascular calcification secondary to CKD., This work was funded by grants BFU2016-78374-R (to DA), BFU2013-45867-R and BFU2016-75360-R (to JL-L and MP-G) from the Ministerio de Economía y Competitividad (MINECO, Spain) and PI13/01726 (to JN-G) from the Instituto de Salud Carlos III (MINECO). We acknowledge cofounding by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea (“Una forma de hacer Europa”). EM-N is recipient of a research contract from the ISCIII (FI14/00033). JD-C and JN-G are members of the ISCIII-RETIC-REDINREN (RD16/0009). TG is funded by the Ramon y Cajal Program (MINECO)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists

  • Pérez-Gordillo, Felipe L.
  • Pérez de Vega, M. Jesús
  • Gerona-Navarro, Guillermo
  • Rodríguez, Y.
  • Alvarez de la Rosa, Diego
  • González-Muñiz, Rosario
  • Martín-Martínez, Mercedes
The mineralocorticoid receptor (MR) belongs to the nuclear receptor superfamily and regulates body fluid and electrolyte balance. In the last years, much effort has been put into the development of non-steroidal MR antagonists that overcome the side effects of the marketed steroid drugs, and can be used for the treatment of hypertension and heart failure, among others. Initially, MR was identified in epithelial cells, however it also plays important roles in non-epithelial tissues. In this sense, it is of interest to discover ligands that might induce different MR conformational changes, leading to specific coregulator interactions, which could confer tissue-specific effects. Different series of non-steroidal ligands with diverse central scaffolds has been described, which shows antihypertensive and cardiorenal protective effects. This review covers a description of different non-steroidal MR antagonist families, with special focus on compounds under clinical development. The analysis of the three-dimensional (3D) structures of non-steroidal MR antagonists in complex with the MR ligand-binding domain (LBD), recently reported, highlights the interactions crucial for binding. The structure-activity relationships of known ligands, together with the insights provided by the 3D structures of ligand - LBD MR complexes, could help in the development of non-steroidal MR antagonists with improved properties., This publication is based upon work from the EU COST Action ADMIRE BM1301 in Aldosterone and Mineralocorticoid Receptor (MR) Physiology and Pathophysiology (www.admirecosteu.com). Also supported by grants from Ministerio de Economia y Competitividad (MINECO, Spain; grant SAF2015-66275- C2-2-R and BFU2016-78374-R), CUNY (CCRG-1532), and the Hostos Office of Academic Affairs, US National Institute of Health (NIGMS) SC2GM111231
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists

  • Pérez-Gordillo, Felipe L.
  • Serrano-Morillas, Natalia
  • Acosta-García, Luz M.
  • Aranda, M. Teresa
  • Passeri, D.
  • Pellicciari, Roberto
  • Pérez de Vega, M. Jesús
  • González-Muñiz, Rosario
  • Alvarez de la Rosa, Diego
  • Martín-Martínez, Mercedes
The mineralocorticoid receptor (MR) belongs to the steroid receptor subfamily of nuclear receptors. MR is a transcription factor key in regulating blood pressure and mineral homeostasis. In addition, it plays an important role in a broad range of biological and pathological conditions, greatly expanding its interest as a pharmacological target. Non-steroidal MR antagonists (MRAs) are of particular interest to avoid side effects and achieve tissue-specific modulation of the receptor. The 1,4-dihydropyridine (1,4-DHP) ring has been identified as an appropriate scaffold to develop non-steroidal MRAs. We report the identification of a novel series of 1,4-DHP that has been guided by structure-based drug design, focusing on the less explored DHP position 2. Interestingly, substituents at this position might interfere with MR helix H12 disposition, which is essential for the recruitment of co-regulators. Several of the newly synthesized 1,4-DHPs show interesting properties as MRAs and have a good selectivity profile. These 1,4-DHPs promote MR nuclear translocation with less efficiency than the natural agonist aldosterone, which explains, at least in part, its antagonist character. Molecular dynamic studies are suggestive of several derivatives interfering with the disposition of H12 in the agonist-associated conformation, and thus, they might stabilize an MR conformation unable to recruit co-activators., This research was funded by grants BFU2016-78374-R and PID2019-105339RB-I00 to D.A.d.l.R., funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe”. RTI-2018-097189-B-C22, PID2021-126423OB-C22 and CSIC (202180E073) to MMM. N.S.-M. was supported by fellowship BES-2014-068280, funded by MCIN/AEI/10.13039/501100011033 and “ESF Investing in your future”., Peer reviewed